The approval is based on the results of the phase 3 VISION trial that evaluated the effectiveness and safety profile of the drug.
Patients involved in the trial who were treated with Pluvicto and standard of care had a 38% decrease in the risk of death, while a statistically significant reduction was also shown in the risk of radiographic disease progression or death compared to standard of care alone.
There were more than 1.4 million new cases and 375,000 deaths in 2020 alone from prostate cancer, and it is the most frequently diagnosed cancer in 112 countries.
